Cargando…
Real-world effectiveness of nirmatrelvir–ritonavir against BA.4 and BA.5 omicron SARS-CoV-2 variants
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917404/ https://www.ncbi.nlm.nih.gov/pubmed/36780911 http://dx.doi.org/10.1016/S1473-3099(23)00056-7 |
| _version_ | 1784886357978513408 |
|---|---|
| author | Wong, Carlos K H Lau, Kristy T K Leung, Gabriel M |
| author_facet | Wong, Carlos K H Lau, Kristy T K Leung, Gabriel M |
| author_sort | Wong, Carlos K H |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9917404 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-99174042023-02-13 Real-world effectiveness of nirmatrelvir–ritonavir against BA.4 and BA.5 omicron SARS-CoV-2 variants Wong, Carlos K H Lau, Kristy T K Leung, Gabriel M Lancet Infect Dis Comment Elsevier Ltd. 2023-06 2023-02-10 /pmc/articles/PMC9917404/ /pubmed/36780911 http://dx.doi.org/10.1016/S1473-3099(23)00056-7 Text en © 2023 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Comment Wong, Carlos K H Lau, Kristy T K Leung, Gabriel M Real-world effectiveness of nirmatrelvir–ritonavir against BA.4 and BA.5 omicron SARS-CoV-2 variants |
| title | Real-world effectiveness of nirmatrelvir–ritonavir against BA.4 and BA.5 omicron SARS-CoV-2 variants |
| title_full | Real-world effectiveness of nirmatrelvir–ritonavir against BA.4 and BA.5 omicron SARS-CoV-2 variants |
| title_fullStr | Real-world effectiveness of nirmatrelvir–ritonavir against BA.4 and BA.5 omicron SARS-CoV-2 variants |
| title_full_unstemmed | Real-world effectiveness of nirmatrelvir–ritonavir against BA.4 and BA.5 omicron SARS-CoV-2 variants |
| title_short | Real-world effectiveness of nirmatrelvir–ritonavir against BA.4 and BA.5 omicron SARS-CoV-2 variants |
| title_sort | real-world effectiveness of nirmatrelvir–ritonavir against ba.4 and ba.5 omicron sars-cov-2 variants |
| topic | Comment |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917404/ https://www.ncbi.nlm.nih.gov/pubmed/36780911 http://dx.doi.org/10.1016/S1473-3099(23)00056-7 |
| work_keys_str_mv | AT wongcarloskh realworldeffectivenessofnirmatrelvirritonaviragainstba4andba5omicronsarscov2variants AT laukristytk realworldeffectivenessofnirmatrelvirritonaviragainstba4andba5omicronsarscov2variants AT leunggabrielm realworldeffectivenessofnirmatrelvirritonaviragainstba4andba5omicronsarscov2variants |